Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ARCH THERAPEUTICS INC

SummaryChartsNewsRatingsCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about ARCH THERAPEUTICS INC
10/18ARCH THERAPEUTICS : Prospectus filed pursuant to Rule 424(b)(3)
PU
10/18ARCH THERAPEUTICS : Provides Corporate Update - Form 8-K
PU
10/18ARCH THERAPEUTICS : Launches Experts in Wound Care Program
AQ
10/13Arch Therapeutics Provides Corporate Update
GL
10/13ARCH THERAPEUTICS : Statement of changes in beneficial ownership of securities
PU
10/12ARCH THERAPEUTICS : Initial statement of beneficial ownership of securities
PU
10/06ARCH THERAPEUTICS : to Present at the LD Micro Main Event
AQ
10/04ARCH THERAPEUTICS : Launches Coverage and Reimbursement Pilot
AQ
10/04ARCH THERAPEUTICS : LD Micro Main Event Conference Presentation
PU
10/01ARCH THERAPEUTICS : Announces Appointment of Larry Hicks to the Board (Form 8-K)
PU
10/01ARCH THERAPEUTICS : Statement of changes in beneficial ownership of securities
PU
09/30ARCH THERAPEUTICS : Announces Appointment of Larry Hicks to the Board
AQ
09/30Arch Therapeutics, Inc. Appoints Larry Hicks to its Board of Directors
CI
09/02ARCH THERAPEUTICS : Prospectus filed pursuant to Rule 424(b)(3)
PU
09/02ARCH THERAPEUTICS : Partners with Lovell Government Services to Expand Distribution Capabi..
PU
09/02ARCH THERAPEUTICS : Partners with Lovell Government Services to Expand Distribution Capabi..
AQ
09/02Arch Therapeutics Partners with Lovell Government Services to Expand Distribution Capab..
CI
08/13Arch Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2..
CI
08/11ARCH THERAPEUTICS : Statement of changes in beneficial ownership of securities
PU
08/11ARCH THERAPEUTICS : Initial statement of beneficial ownership of securities
PU
07/13ARCH THERAPEUTICS : Ladenburg Thalmann 2021 Healthcare Conference Presentation
PU
07/12ARCH THERAPEUTICS : Completes Leadership Team with Appointment of Dan Yrigoyen as Vice Pre..
AQ
07/07Arch Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference, July..
GL
06/10ARCH THERAPEUTICS : LD Micro Invitational XI Presentation
PU
06/02Arch Therapeutics to Present at the LD Micro Invitational XI, June 8 - 10, 2021
GL
05/10ARCH THERAPEUTICS : Initial statement of beneficial ownership of securities
PU
05/10Arch Therapeutics' AC5® Advanced Wound System Presents with Recognition at the 2021 Sym..
GL
05/10Arch Therapeutics’ Ac5® Advanced Wound System Presents with Recognition at the 2021 Sym..
CI
05/06ARCH THERAPEUTICS : Prospectus filed pursuant to Rule 424(b)(3)
PU
05/06ARCH THERAPEUTICS : Quarterly report pursuant to Section 13 or 15(d)
PU
05/06Arch Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended March 31,..
CI
05/03Arch Therapeutics Appoints Michael S. Abrams its Chief Financial Officer
GL
05/03Arch Therapeutics, Inc. Announces Executive Changes
CI
04/27Arch Therapeutics to Present AC5® Advanced Wound System at 2021 Symposium on Advanced W..
GL
04/19ARCH THERAPEUTICS : Prospectus filed pursuant to Rule 424(b)(3)
PU
04/19Arch Therapeutics Provides Corporate Update on Commercialization Efforts and Clinical R..
GL
04/19Arch Therapeutics, Inc. to Launch Ac5 Advanced Wound System
CI
03/10ARCH THERAPEUTICS : Notice of Effectiveness
PU
03/02Arch Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference, Ma..
GL
02/26ARCH THERAPEUTICS : General form of registration statement for all companies including fac..
PU
02/25ARCH THERAPEUTICS : Official notice of an offering of securities that is made without regi..
PU
02/18Arch Therapeutics Announces Closing of $6.9 Million Private Placement
GL
02/18Arch Therapeutics, Inc. announced that it has received $6.9 million in funding
CI
02/12ARCH THERAPEUTICS : Quarterly report pursuant to Section 13 or 15(d)
PU
02/12Arch Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 3..
CI
02/12Arch Therapeutics Announces $6.9 Million Private Placement
GL
02/12Arch Therapeutics, Inc. announced that it expects to receive $6.9 million in funding
CI
02/01ARCH THERAPEUTICS : Notice of Effectiveness
PU
01/22ARCH THERAPEUTICS : Schedule filed to report acquisition of beneficial ownership of 5% or ..
PU
01/05ARCH THERAPEUTICS : to Present at the H.C. Wainwright BioConnect Conference, January 11 - ..
AQ
01/04Arch Therapeutics Announces Distribution Agreement with Buffalo Supply
CI
01/04Arch Therapeutics Announces Distribution Agreement with Buffalo Supply, Inc.
GL
2020Arch Therapeutics, Inc. Announces Retirement of Richard Davis as CFO, Effective June 30..
CI
2020Arch Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, ..
CI
2020Arch Therapeutics to Present at the 13th Annual LD Micro Main Event Conference
GL
2020ARCH THERAPEUTICS : Raises Approximately $1.1 Million with Convertible Note Issuance
AQ
2020Arch Raises Approximately $1.1 Million with Convertible Note Issuance
GL
2020ARCH THERAPEUTICS : rsquo; AC5 Advanced Wound System Presented at the 2020 Symposium on Ad..
AQ
2020Arch Therapeutics' AC5 Advanced Wound System Presented at the 2020 Symposium on Advance..
GL
2020Arch Therapeutics, Inc. announced that it has received $1.05 million in funding
CI
2020ARCH THERAPEUTICS : to Present at the Virtual Investor KOL Roundtable
AQ
2020Arch Therapeutics, Inc. to Present at the Virtual Investor KOL Roundtable
GL
2020ARCH THERAPEUTICS : Announces Presentations on AC5 Advanced Wound System at the 2020 Sympo..
AQ
2020Arch Therapeutics Announces Presentations on AC5 Advanced Wound System at the 2020 Symp..
GL
2020ARCH THERAPEUTICS : Positioned For Multiple Catalysts In 2020-21; Approved FDA and EU Mark..
AQ
2020With FDA and EU Marketing Authorizations in Hand, 2020 and 2021 Can Be Catalyst Years f..
NE
2020ARCH THERAPEUTICS : to Present at the H.C. Wainwright 22nd Annual Global Investment Confer..
AQ
2020Arch Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Confe..
GL
2020Arch Therapeutics to Present at The LD 500 Virtual Conference on Tuesday, September 1 a..
GL
2020Arch Therapeutics Novel Self-Assembling Agent, AC5-GTM, for Use in Endoscopic Procedure..
GL
2020Arch Therapeutics, Inc. Announces the Release of Research from the AC5
CI
2020ARCH THERAPEUTICS : Novel Self-Assembling Agent for Use in Endoscopic Procedures to be Pre..
AQ
2020Arch Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2..
CI
2020ARCH THERAPEUTICS : to Present at the Virtual Investor Fireside Chat Series
AQ
2020Arch Raises $1.4 Million with Convertible Note Issuance and Warrant Reprice
GL
1  2  3Next